Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Objectives: To investigate whether the conclusion of a recent systematic review and network meta-analysis (Cipriani et al) that antidepressants are more efficacious than placebo for adult depression was supported by the evidence. Design: Reanalysis of a systematic review, with meta-analyses. Data sources: 522 trials (116 477 participants) as reported in the systematic review by Cipriani et al and clinical study reports for 19 of these trials. Analysis: We used the Cochrane Handbook’s risk of bias tool and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to evaluate the risk of bias and the certainty of evidence, respectively. The impact of several study characteristics and publication status was estimated using pairwise subgroup meta-analyses. Results: Several methodological limitations in the evidence base of antidepressants were either unrecognised or underestimated in the systematic review by Cipriani et al. The effect size for antidepressants versus placebo on investigator-rated depression symptom scales was higher in trials with a ‘placebo run-in’ study design compared with trials without a placebo run-in design (p=0.05). The effect size of antidepressants was higher in published trials compared with unpublished trials (p<0.0001). The outcome data reported by Cipriani et al differed from the clinical study reports in 12 (63%) of 19 trials. The certainty of the evidence for the placebo-controlled comparisons should be very low according to GRADE due to a high risk of bias, indirectness of the evidence and publication bias. The mean difference between antidepressants and placebo on the 17-item Hamilton depression rating scale (range 0–52 points) was 1.97 points (95% CI 1.74 to 2.21). Conclusions: The evidence does not support definitive conclusions regarding the benefits of antidepressants for depression in adults. It is unclear whether antidepressants are more efficacious than placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies without active placebo are considered to be at unclear or high risk of performance bias (Munkholm 2019).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Munkholm 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of antidepressant treatment for depression is modest compared with placebo [2, 3]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541 · cited 10×
“They classified the trials as low risk of bias if none of the domains assessed were rated as high risk of bias and three or less were rated as unclear risk; moderate if one domain was rated as high risk of bias or none were rated as high risk of bias but four or more were rated as unclear risk; and all other cases wer…”
InfluentialThe cost of dichotomising continuous variables
Altman, D. G., & Royston, P. (2006) · BMJ · doi:10.1136/bmj.332.7549.1080 · Cited by 2,688
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 2×
“antidepressant trials remain unpublished or are inadequately reported.(9) Cipriani et al(5) included 436 published and 86 unpublished studies, but as many as a thousand antidepressant studies may have been conducted.”
BackgroundIntHout, J., Ioannidis, J. P., & Borm, G. F. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-25 · Cited by 2,419 · cited 1×
“For the comparisons between antidepressants and placebo on rating scales, we used the Hartung-Knapp-SidikJonkman approach because it results in fewer type I errors than the DerSimonian and Laird approach.(16) We based our analyses on the number of participants from Cipriani et al’s ‘efficacy’ analyses.”
MethodAntidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
GRADE guidelines: 8. Rating the quality of evidence—indirectness
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Falck-Ytter, Y., Jaeschke, R., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.014 · Cited by 1,843 · cited 1×
“Downgrading due to the indirectness of the network meta-analysis’ methodology should also be considered.(38) Taken together, the certainty of evidence should be ‘very low’.”
BackgroundIndustry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697 · cited 1×
“Some argue that ‘vested interests’ should also be considered, since industry sponsored drug studies lead to more favourable effects than other studies by mechanisms that are not explained by the usual bias domains.(26) We explored whether industry sponsorship was associated with larger effect estimates, by performing…”
Research works printed but not linked: 1
- Sharma T Effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin - norepinephrine reuptake inhibitors (SNRIs) on suicidality, violence, and quality of life (PhD Thesis): University of Copenhagen, 2018.
Cited by
Items 101–166 of 166
Democracy Therapy: Lessons from ThriveNYC
Belkin, G. S. (2023) · Daedalus · doi:10.1162/daed_a_02034 · Cited by 2
Hengartner, M. P., Jakobsen, J. C., Sorensen, A., & Plöderl, M. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3tuzy · Cited by 2
Munkholm, K., Homan, S., & Homan, P. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/srzx5 · Cited by 2
Self-citationComment on: "Should Antidepressants be Avoided in Pregnancy?"
Braillon, A., Bewley, S., Blumsohn, A., & Naudet, F. (2023) · Drug Safety · doi:10.1007/s40264-023-01308-1 · Cited by 2
Análisis de variables transdiagnósticas en el consumo problemático de alcohol y depresión en Ecuador
Sánchez-Puertas, R. N. (2024) · doi:10.48035/tesis/2454/50511 · Cited by 2
Die Geschichte des medizinischen Modells der Depression – mit (fast) all ihren Vor- und Nachteilen
Padberg, T., & Plöderl, M. (2025) · Kontext · doi:10.13109/kont.2025.56.2.125 · Cited by 1
Beneath the tip of the iceberg: treatment of neuropsychiatric comorbidities in tic disorders
Abi‐Jaoude, E., Gorman, D. A., & Sandor, P. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-13554-5.00008-0 · Cited by 1
The first on the dark side of the moon: Revisiting the first nonblind placebo trial
Gaab, J., Nascimento, A. F., Wehlage, C., & Park, L. C. (2026) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2026.112565 · Cited by 1
The nature of depression and the biomedical model: ten questions in search of an answer
Fountoulakis, K. Ν. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03943-5 · Cited by 1
Bonnet, U. (2026) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000681 · Cited by 1
A conceptual framework for addressing treatment withdrawal effects across the evidence pathway
Mathioudakis, A. G., Clarke, M. J., Vestbo, J., & Kontopantelis, E. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112467 · Cited by 1
Holper, L. (2019) · Research Synthesis Methods · doi:10.1002/jrsm.1393 · Cited by 1
Pharmakotherapie der Depression – neue Erkenntnisse und neue Strategien
Hullmeine, L., & Bschor, T. (2021) · PiD - Psychotherapie im Dialog · doi:10.1055/a-1215-1756 · Cited by 1
Combination Antidepressant Therapy vs Monotherapy—Further Considerations—Reply
Henssler, J. F., Bschor, T., & Baethge, C. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.1385 · Cited by 1
Tercelli, I., McPherson, S., & Senra, H. (2024) · British Journal of Psychotherapy · doi:10.1111/bjp.12879 · Cited by 1
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Kaiserman, A., Vanderijst, L., & Kornreich, C. (2024) · Psychiatria Danubina · doi:10.24869/psyd.2024.174 · Cited by 2
“Indeed, a large fraction of patients suffering from depression do not respond ad - equately to antidepressant treatment (Cipriani et al. 2018, Hengartner & Plöderl 2018, Kirsch 2014, Munkholm et al. 2019).”
The role of psilocybin in depressive disorders
Najib, J. S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2396536 · Cited by 1
“A recent systematic review with meta-analyses of 522 trials did not support definitive conclusions regarding the benefits of antidepressants in managing depressive disorders and noted the uncertainty of whether antidepressants were more efficacious than placebo 56 .”
Eder, J., Kräter, M., Kirschbaum, C., Gao, W., Wekenborg, M., Penz, M., Rothe, N., Guck, J. R., Wittwer, L. D., & Walther, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01902-z · Cited by 1
“Nevertheless, both conditions cause severe functional impairment and there are major difficulties in reducing the high prevalence rates [4, 5 ] and improving DD treatment [6, 7], with up to 30% of patients not achieving remission despite multiple treatment attempts [8–10].”
Walther, A., Kräter, M., Kirschbaum, C., Gao, W., Wekenborg, M., Penz, M. S., Rothe, N., Guck, J. R., Wittwer, L. D., & Eder, J. (2022) · medRxiv · doi:10.1101/2022.09.23.22280275 · Cited by 1
“2017) and improving DD treatment (Munder et al., 2019; Munkholm et al., 2019), with 33% of”
BackgroundWhy it is important to discuss what antidepressants do
Moncrieff, J., & Horowitz, M. A. (2022) · BMJ · doi:10.1136/bmj.o2350 · Cited by 2
Good news regarding SSRI safety in Danish meta-analysis
Hieronymus, F., Lisinski, A., Näslund, J., & Eriksson, E. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.42
“Of note in this context is thatMunkholm and co-workers in a recent SSRI-critical meta-analysis (Munkholm et al., 2019) noted higher effect sizes for antidepressants in company-independent trials than in those conducted by the drug industry.”
ResultInnovative Psychiatrieforschung im Blickpunkt
Klein, F. (2019) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-019-0250-8
Vinberg, M. (2020) · Bipolar Disorders · doi:10.1111/bdi.12893
Miller, E. W., Shoup, D. S., Recktenwald, M., & Recktenwald, E. W. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100016
Those who control evidence control evidence based medicine
Spielmans, G. I. (2020) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2020.118
“These reviews frequently ignore the fact that unfavourable findings are sometimes unpublished and that studies are often designed to favour the sponsored product (15,16).”
BackgroundOmega-3 and Cognition: The Influence of Omega-3 Fatty Acids on Cognitive Functions in Youths
Emery, S. (2021) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-195874
Niedermoser, D. W., Kalak, N., Meyer, M., Schweinfurth, N., Walter, M., & Lang, U. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041925
“There are also many questions about the efficacy of antidepressants, as mentioned in the introduction [2,3,9,10,36].”
BackgroundArnold, M. M. (2021) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-23698
Antidepressiva – wirksam und gut verträglich?
Plöderl, M., & Padberg, T. (2021) · PiD - Psychotherapie im Dialog · doi:10.1055/a-1215-1638 · Cited by 1
“Die Kontroverse entzündet sich an der Bedeutsamkeit der gefundenen Unterschiede und an Problemen mit den Forschungsmethoden, welche zu einer Überschätzung der Wirksamkeit führen [6][8][9].”
BackgroundInfluentialBoesen, K., Paludan‐Müller, A. S., & Ioannidis, J. P. A. (2021) · medRxiv · doi:10.1101/2021.12.07.21267067
“Several design issues may affect the external validity of psychiatric drug trials, as already highlighted for trials of antidepressants 5 and antipsychotics.”
Self-citationAlloy, L. B., Chat, I. K.-Y., Grehl, M. M., Kautz, M. M., Dunning, E. E., Adogli, Z. V., Smith, L. T., Walsh, R. F. L., & Stephenson, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00225-9
Dinger, U., & Schauenburg, H. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-22601-4.00005-x · Cited by 1
The underutilization of medications for alcohol use disorders is a sensible choice
Braillon, A., & Naudet, F. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.07.023
Neto, A. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-14092023-140523
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Wood, E., Bright, J., Hsu, K., Goel, N., Ross, J. W. G., Hanson, A., Teed, R., Poulin, G., Denning, B., Corace, K., et al. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.230715-f
Nouvelles méthodes pour le développement de Core Outcome Sets : l'exemple de la dépression
Chevance, A. (2020) · theses.fr (ABES) · doi:10.70675/a9c04184zecb2z426dza310z44d7321107e4
Tantam, D. (2024) · Routledge eBooks · doi:10.4324/9781032709444
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Antidepressant Medication and Psychotherapy: Why It Matters
Chiesa, M. (2024) · British Journal of Psychotherapy · doi:10.1111/bjp.12938
The placebo effect in psychotherapy
Gaab, J. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-29884-4.00021-2
Ahmadzad-Asl, M., Kermani, R. J. N., Shekouh, D., arshadi, Arshadi, M., Mohamadi, S., Shirdel, S., Davoudi, F., Lanctôt, K. L., Ameis, S. H., et al. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10665 · Cited by 1
Manook, A., Hiergeist, A., Liebisch, G., Dischinger, U., Petrera, A., Schwarzbach, J. V., Gessner, A., Gruber, O., & Baghai, T. C. (2025) · medRxiv · doi:10.64898/2025.12.01.25341376
Jørgensen, C. K., Juul, S., Siddiqui, F., Barbateskovic, M., Munkholm, K., Hengartner, M. P., Kirsch, I., Gluud, C. N., & Jakobsen, J. C. (2021) · Figshare · doi:10.6084/m9.figshare.15178659
Self-citationEEG-Neurofeedback: Entwicklung und Evaluation eines depressionsspezifischen Trainingsprotokolls
Tretter, P. (2025) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.35018
Jørgensen, C. K., Juul, S., Siddiqui, F., Horowitz, M. A., Moncrieff, J., Munkholm, K., Hengartner, M. P., Kirsch, I., Gluud, C., & Jakobsen, J. C. (2023) · Figshare · doi:10.6084/m9.figshare.22618499
Self-citationJørgensen, C. K., Juul, S., Siddiqui, F., Horowitz, M. A., Moncrieff, J., Munkholm, K., Hengartner, M. P., Kirsch, I., Gluud, C., & Jakobsen, J. C. (2023) · Figshare · doi:10.6084/m9.figshare.22618496
Self-citationJørgensen, C. K., Juul, S., Siddiqui, F., Barbateskovic, M., Munkholm, K., Hengartner, M. P., Kirsch, I., Gluud, C., & Jakobsen, J. C. (2021) · Figshare · doi:10.6084/m9.figshare.15178662
Self-citationEsteller-Collado, G. (2024) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
The assessment of suicidality in psychiatric trials: a protocol for a scoping review
Faltermeier, P., Juul, S., Siddiqui, F., Yücel, D., Horowitz, M. A., Moncrieff, J., Gluud, C. N., & Jakobsen, J. C. (2025) · Systematic Reviews · doi:10.1186/s13643-025-03026-4
“Minimal important difference The MID is often unclear [11–13].”
Can We Help Adolescents Improve Their Mental Health with a Healthy Diet? A Formative Study
Wardle, C. M. (2023) · Tuwhera (Auckland University of Technology)
The Effect of Side Effects on Antidepressant Efficacy : A Meta-Regression
Hadžajlić, A. (2025) · Tampere University Institutional Repository (Tampere University)
Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybinPreprint
Claydon, M. D. B., Hinchcliffe, J. K., Bartlett, J. M., Golden, C. T., Thomas, C. W., Gilmour, G., Mellor, J. R., Za, B., & Robinson, E. S. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.709133
“Indeed, an estimated 30-40% of patients are failed by current treatments, and side-50 effects associated with these long-standing treatment options can be significant[11, 12].”
Vidal, C. (2025) · Champ social eBooks · doi:10.3917/chaso.levy.2025.01.0111
Stopping antidepressants safely
Horowitz, M. A., & Perry, T. L. (2026) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v18i1.5431
Psychologie positive et processus cognitifs dans le traitement de la dépression
Puechbroussou, B. (2024) · theses.fr (ABES) · doi:10.70675/d5b7c126zcc6fz419ez9e9dz64faf24a0880
Apel, K., Scheel-Barteit, J., Berking, M., Kühlein, T., & Sebastião, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-62116-y
Therapie und Prävention psychischer Störungen
Hengartner, M. P. (2026) · Angewandte Psychologie Kompakt · doi:10.1007/978-3-662-72845-1_5
CURRENT COUNSELLING VIEWS AND THE MEDICAL MODEL: AN EXPLORATION OF THE TENSION
Sheikh, J. (2024) · AUSpace (Athabasca University)
Dinger, U., & Schauenburg, H. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21352-6.00010-9
¿Puede un antidepresivo cambiar una vida? Evidencia, experiencia y relevancia clínica
Baca, N. E. (2026) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v46i2.1320
Psychedelics in the Future of Global Mental Healthcare
Aleksandrova, L. R., Thiessen, K. A., Chen, F. X. F., Phillips, A. G., Schütz, C. G., & Krausz, M. (2026) · Springer eBooks · doi:10.1007/978-3-319-70134-9_174-1
Beyond reasonable doubt: antidepressants and the limits of scientific critique
Goulder, J. (2026) · Medical History · doi:10.1017/mdh.2026.10090
Metadata
- Authors
- Munkholm, K., Paludan-Müller, A. S., & Boesen, K.
- Affiliations
- Rigshospitalet (DK)
- Corresponding author
- Munkholm, Klaus
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-06
- Volume
- 9
- Issue
- 6
- Pages
- e024886
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC6597641
- OpenAlex
- W2954134279
- Semantic Scholar
- 1f02503fe1b4290d23f35fdcf0ce927d794271ed
- Cited by
- 151
- References
- 43
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 17 · 2023: 31 · 2022: 20 · 2021: 29 · 2020: 15 · 2019: 11
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Nordic Cochrane Centre
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- antidepressants, depression, placebo response, risk of bias, publication bias, clinical study reports, quality of evidence, Hamilton Depression Rating Scale, antidepressant efficacy
- MeSH terms
- Network Meta-Analysis, Network Meta-Analysis as Topic, Systematic Reviews as Topic, Adult, Antidepressive Agents, Depression, Humans, Meta-Analysis as Topic, Bias, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.